Assessment of medical treatments for menorrhagia

Robert W. Shaw
In: BJOG: An International Journal of Obstetrics & Gynaecology · 1994 · vol. 101(s11) , pp. 15–18 · doi:10.1111/j.1471-0528.1994.tb13690.x · PMID:8043556 · W2142893017
article OA: closed CC0 ⤵ 18 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review assessed medical treatments for menorrhagia, finding progestogens modestly effective in anovulatory women, prostaglandin inhibitors and antifibrinolytics useful, GnRH analogues effective but with contraindications, and danazol at 200mg daily highly effective and well-tolerated.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ABSTRACT Although usually not life‐threatening, dysfunctional uterine bleeding (DUB) can cause discomfort and disruption to life for many women. It has been poorly researched in the past, primarily because of difficulties in trying to accurately measure blood loss and response to treatment. There are several different therapies currently available but, for many, actual evidence of their efficacy is lacking from scientific data. Progestogens are the most frequently prescribed drugs for the treatment of DUB. Data support their use in anovulatory women but a number of comparative trials have shown that an overall reduction in blood loss of only 20% is achieved in ovulatory women. Their use, therefore, must be questioned as the first line of treatment. Combined oral contraceptives were at one time popular but whether the low‐dose, current generation pills are equally effective awaits appropriate trials. Prostaglandin synthetase inhibitors can be useful, with up to a third of women with menorrhagia benefiting from a reduction of between 25 % and 35 % in blood loss. A proportionally greater reduction is seen in women with more excessive bleeding. Antifibrinolytic drugs have been shown to reduce menstrual blood loss in DUB by 50% and would be useful in women in whom oestrogens are contraindicated. Gonadotrophin‐releasing hormone analogues are highly effective because of their ability to induce amenorrhoea, but long‐term use is contraindicated because of their hypo‐oestrogenic effects. One other effective therapy for menorrhagia has been danazol. At a dosage of 200 mg daily, danazol has been shown to be highly effective in several open and randomised comparative trials, with a consistent reduction of blood loss of up to 75 % being achieved with maintenance of a regular menstrual cycle. Reducing the dose to 100 mg daily often results in cycle irregularities, whereas increasing the dose to 400 mg daily induces amenorrhoea. A daily dose of 200 mg of danazol is well tolerated and should be considered as a first‐line option in DUB presenting as menorrhagia requiring medical management.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Cited by (18)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK